webcast

Lupus Management in 2015

PRESENTER: Kathryn Dao, MD

Associate Director of Rheumatology Research
Baylor Research Institute
Arthritis Care and Research Center
Dallas, TX

Credits: 0.5

Release Date: April 30, 2015

Target Audience: This activity has been designed to meet the educational needs of rheumatologists, physician assistants, and nurse practitioners involved in the care of patients with lupus.

Learning Objectives: After the completion of this activity, participants should be able to:

  • Summarize the management options for cutaneous lupus
  • Describe the benefits of hydroxychloroquine
  • Define the novel targets for potential new lupus therapies and the rationale for each
  • Physician Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of Purdue University College of Pharmacy and Focus Medical Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation: Purdue University College of Pharmacy designates this enduring activity for a maximum of
    0.5 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Disclosure Statement: All faculty and staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

    All additional planning committee members, reviewers and Focus Medical Communications and Purdue University College of Pharmacy staff have no relationships to disclose.

    Dr. Dao has received grants and/or research support from Amgen, Celgene, Genentech, Novartis, Pfizer and UCB.